Clinical Trials Directory

Trials / Completed

CompletedNCT02845934

Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
248 (actual)
Sponsor
Centre Hospitalier Universitaire de Besancon · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This Study evaluates the performance (sensitivity, specificity, positive and negative predictive value values and likelihood ratios) of the DNA detection test for the diagnosis of mucormycosis by comparing it to the routine tests such as CT scan aspects, histopathology, microscopy and fungal culture, in a test group of 52 patients including : * patients at high-risk according to the EORTC/MSG criteria (patients with prolonged severe neutropenia, receiving corticosteroids or T-cell suppressors, recipients of allogeneic HSCT, or inherited severe immunodeficiency), * patients with other predisposing factors of invasive mould disease ( diabetes, AIDS, haematological malignancies or solid tumours, trauma, burns); Patients already diagnosed with probable or proven mucormycosis irrespective of underlying conditions.

Detailed description

The patients eligible for this study will already be hospitalized with repeated monitoring of clinical and biological parameters. Participation in the study will result in an additional sampling of blood (estimated volume 6 mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a maximum of 8 weeks. vials will be added to the routine sampling of these patients (ie, at the time of routine sampling for galactomannan antigemia), and no new sampling procedure will be required.

Conditions

Interventions

TypeNameDescription
OTHERblood sampleadditional sampling of blood (estimated volume 6 mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a maximum of 8 weeks.

Timeline

Start date
2014-01-01
Primary completion
2017-07-01
Completion
2018-01-01
First posted
2016-07-27
Last updated
2021-03-11

Locations

10 sites across 1 country: France

Source: ClinicalTrials.gov record NCT02845934. Inclusion in this directory is not an endorsement.